Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
3
60%
Ph phase_3
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Not yet recruiting5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

not_yet_recruiting5100%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_2

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

NCT07662811
not_yet_recruitingphase_3

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

NCT07672223
not_yet_recruitingphase_1

SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors

NCT07622225
not_yet_recruitingphase_2

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

NCT07332533
not_yet_recruitingphase_2

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

NCT06998771

Clinical Trials (5)

Showing 5 of 5 trials
NCT07662811Phase 2

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT07672223Phase 3

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

Not Yet Recruiting
NCT07622225Phase 1

SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors

Not Yet Recruiting
NCT07332533Phase 2

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not Yet Recruiting
NCT06998771Phase 2

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5